Feasibility of home-based exercise training during adjuvant treatment for metastatic castrate-resistant prostate cancer patients treated with an androgen receptor pathway inhibitor (EXACT)

被引:4
作者
Brown, Malcolm [1 ]
Murphy, Marie H. [2 ,3 ]
McAneney, Helen [4 ,5 ]
McBride, Ken [6 ]
Crawford, Ffiona [6 ]
Cole, Aidan [7 ,8 ]
O'Sullivan, Joe M. [7 ,8 ]
Jain, Suneil [7 ,8 ]
Prue, Gillian [1 ]
机构
[1] Queens Univ Belfast, Med Biol Ctr, Sch Nursing & Midwifery, 97 Lisburn Rd, Belfast BT9 7BL, North Ireland
[2] Ulster Univ, Ctr Exercise Med Phys Act & Hlth, Sch Sport, Belfast, North Ireland
[3] Univ Edinburgh, Sch Educ & Sport, Edinburgh, Scotland
[4] Ulster Univ, Sch Med, Northern Ireland Publ Hlth Res Network, Belfast, North Ireland
[5] Univ Coll Dublin, Sch Nursing Midwifery & Hlth Syst, Dublin, Ireland
[6] Northern Ireland Canc Res Consumer Forum, Belfast, North Ireland
[7] Belfast Hlth & Social Care Trust, Northern Ireland Canc Ctr, Belfast, North Ireland
[8] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, North Ireland
关键词
Exercise; Feasibility; Metastatic prostate cancer; Functional fitness; Health-related quality of life; QUALITY-OF-LIFE; DEPRIVATION THERAPY; BODY-COMPOSITION; FUNCTIONAL ASSESSMENT; PHYSICAL-ACTIVITY; MEN; ENZALUTAMIDE; STRENGTH; MECHANISMS; COUNTRIES;
D O I
10.1007/s00520-023-07894-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundExercise is an effective adjuvant therapy that can alleviate treatment-related toxicities for men with prostate cancer (PC). However, the feasibility of delivering exercise training to men with advanced disease and the wider impact on clinical outcomes remain unknown. The purpose of the EXACT trial was to determine the feasibility and effects of home-based exercise training in men with metastatic castrate-resistant prostate cancer (mCRPC).MethodsPatients with mCRPC receiving ADT + an androgen receptor pathway inhibitor (ARPI) were prescribed 12 weeks of home-based, remotely monitored, moderate intensity, aerobic and resistance exercise. Feasibility was assessed using recruitment, retention and adherence rates. Safety and adverse events were monitored throughout, with functional and patient-reported outcomes captured at baseline, post-intervention and at 3-month follow-up.ResultsFrom the 117 screened, 49 were deemed eligible and approached, with 30 patients providing informed consent (61% recruitment rate). Of those who consented, 28 patients completed baseline assessments, with 24 patients completing the intervention and 22 completing follow-up (retention rates: 86% and 79% respectively). Task completion was excellent throughout, with no intervention-related adverse events recorded. Self-reported adherence to the overall intervention was 82%. Exercise training decreased mean body mass (-1.5%), improved functional fitness (> 10%) and improved several patient-reported outcomes including clinically meaningful changes in fatigue (p = 0.042), FACT-G (p = 0.054) and FACT-P (p = 0.083), all with moderate effect sizes.ConclusionHome-based exercise training, with weekly remote monitoring, was feasible and safe for men with mCRPC being treated with an ARPI. Given that treatment-related toxicities accumulate throughout the course of treatment, and as a result, negatively impact functional fitness and health-related quality of life (HRQoL), it was positive that exercise training improved or prevented a decline in these clinically important variables and could better equip patients for future treatment. Collectively, these preliminary feasibility findings support the need for a definitive, larger RCT, which downstream may lead to the inclusion of home-based exercise training as part of adjuvant care for mCRPC.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer
    Kenfield, Stacey A.
    Van Blarigan, Erin L.
    Panchal, Neil
    Bang, Alexander
    Zhang, Li
    Graff, Rebecca E.
    Chen, Yea-Hung
    Ryan, Charles J.
    Luke, Anthony
    Newton, Robert U.
    Tenggara, Imelda
    Schultz, Brooke
    Wang, Elizabeth
    Lavaki, Emil
    Zuniga, Kyle
    Pinto, Nicole
    Borno, Hala
    Aggarwal, Rahul
    Friedlander, Terence
    Koshkin, Vadim S.
    Harzstark, Andrea
    Small, Eric
    Chan, June M.
    CANCER MEDICINE, 2021, 10 (22): : 8058 - 8070
  • [22] Feasibility of a supervised and home-based tailored exercise intervention in head and neck cancer patients during chemoradiotherapy
    Kok, Annemieke
    Passchier, Ellen
    May, Anne M.
    van den Brekel, Michiel W. M.
    Jager-Wittenaar, Harriet
    Veenhof, Cindy
    de Bree, Remco
    Stuiver, Martijn M.
    Speksnijder, Caroline M.
    EUROPEAN JOURNAL OF CANCER CARE, 2022, 31 (06)
  • [23] "Natural course" of disease in patients with metastatic castrate-resistant prostate cancer: Survival and prognostic factors without life-prolonging treatment
    Loeffeler, Sven
    Weedon-Fekjaer, Harald
    Wang-Hansen, Marte Sofie
    Sebakk, Karin
    Hamre, Hanne
    Haug, Erik S.
    Fossa, Sophie D.
    SCANDINAVIAN JOURNAL OF UROLOGY, 2015, 49 (06) : 440 - 445
  • [24] Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors
    Zhong, Ying Yan
    Anton, Angelyn
    Xie, Owen
    Tan, Natalie
    O'Haire, Sophie
    Maleki, Sam
    Inderjeeth, Andrisha-Jade
    Parente, Phillip
    Spain, Lavinia
    Gibbs, Peter
    Tran, Ben
    JCO ONCOLOGY PRACTICE, 2024, 20 (09) : 1231 - 1242
  • [25] FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer
    Anscher, Mitchell S.
    Chang, Elaine
    Gao, Xin
    Gong, Yutao
    Weinstock, Chana
    Bloomquist, Erik
    Adeniyi, Oluseyi
    Charlab, Rosane
    Zimmerman, Sarah
    Serlemitsos-Day, Maritsa
    Ning, Yang Min
    Mayrosh, Ruth
    Fuller, Barbara
    Trentacosti, Ann Marie
    Gallagher, Pamela
    Bijwaard, Karen
    Philip, Reena
    Ghosh, Soma
    Fahnbulleh, Frances
    Diggs, Felicia
    Arora, Shaily
    Goldberg, Kirsten B.
    Tang, Shenghui
    Amiri-Kordestani, Laleh
    Pazdur, Richard
    Ibrahim, Amna
    Beaver, Julia A.
    ONCOLOGIST, 2021, 26 (02) : 139 - 146
  • [26] Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer
    Narayan, Vivek
    Patel, Miraj Y.
    Teitsson, Siguroli
    Rosenblatt, Lisa
    Yin, Xin
    Pivneva, Irina
    Gao, Sophie
    Sundar, Manasvi
    Betts, Keith A.
    CLINICAL GENITOURINARY CANCER, 2024, 22 (06)
  • [27] Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen
    Fryzek, Jon P.
    Reichert, Heidi
    Summers, Nicholas
    Townes, Lindsay
    Deuson, Robert
    Alexander, Dominik D.
    Vanderpuye-Orgle, Jackie
    PLOS ONE, 2018, 13 (04):
  • [28] Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer
    Gupta, Sounak
    Vanderbilt, Chad
    Abida, Wassim
    Fine, Samson W.
    Tickoo, Satish K.
    Al-Ahmadie, Hikmat A.
    Chen, Ying-Bei
    Sirintrapun, Sahussapont J.
    Chadalavada, Kalyani
    Nanjangud, Gouri J.
    Bialik, Ann
    Morris, Michael J.
    Scher, Howard I.
    Ladanyi, Marc
    Reuter, Victor E.
    Gopalan, Anuradha
    PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (03) : 507 - 516
  • [29] Feasibility of a tailored home-based exercise intervention during neoadjuvant chemotherapy in breast cancer patients
    Sturgeon, Kathleen M.
    Smith, Amanda M.
    Federici, Elizabeth H.
    Kodali, Namratha
    Kessler, Renee
    Wyluda, Edward
    Cream, Leah, V
    Ky, Bonnie
    Schmitz, Kathryn H.
    BMC SPORTS SCIENCE MEDICINE AND REHABILITATION, 2022, 14 (01)
  • [30] Feasibility of a tailored home-based exercise intervention during neoadjuvant chemotherapy in breast cancer patients
    Kathleen M. Sturgeon
    Amanda M. Smith
    Elizabeth H. Federici
    Namratha Kodali
    Renée Kessler
    Edward Wyluda
    Leah V. Cream
    Bonnie Ky
    Kathryn H. Schmitz
    BMC Sports Science, Medicine and Rehabilitation, 14